NT-proBNP is superior to ST2 and Galectin-3 cardiac markers in identifying carcinoid heart disease in small bowel NET patients

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD. Aim(s): To explore the value of markers NTP, GAL3 and ST2 in identifying CHD in sbNET patients. Materials and Methods: 3 groups of sbNET patients (n = 37) were identified from the Liver Research BioBank; CHD (Group A, n = 10), non-functional (Groups B, n = 12, normal chromogranin A (CgA), 5HIAA, BNP), functional (Group C, n = 15, increased CgA & urine 5HIAA, normal BNP). Analysis was performed using NTP (
    Original languageEnglish
    Pages (from-to)44
    Number of pages1
    JournalNeuroendocrinology
    Volume103
    DOIs
    Publication statusPublished - 2016

    Keywords

    • 5 hydroxyindoleacetic acid
    • Kruskal Wallis test
    • amino terminal pro brain natriuretic peptide
    • biobank
    • biological marker
    • carcinoid syndrome
    • chromogranin A
    • clinical article
    • controlled study
    • endogenous compound
    • galectin 3
    • human
    • human tissue
    • liver
    • neuroendocrine tumor
    • rank sum test
    • small intestine
    • urine

    Fingerprint

    Dive into the research topics of 'NT-proBNP is superior to ST2 and Galectin-3 cardiac markers in identifying carcinoid heart disease in small bowel NET patients'. Together they form a unique fingerprint.

    Cite this